MATURE RESULTS FROM A PHASE II TRIAL OF BRENTUXIMAB VEDOTIN PLUS ADRIAMYCIN AND DACARBAZINE WITHOUT RADIATION IN NON‐BULKY LIMITED STAGE CLASSICAL HODGKIN LYMPHOMA

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hematological oncology 2021-06, Vol.39 (S2)
Hauptverfasser:	Abramson, J. S., Bengston, E. M., Redd, R., Barnes, J. A., Takvorian, T., Sokol, L., Lansigan, F., Armand, P., Shah, B., Jacobsen, E., Martignetti, R., Turba, E., Metzler, S. R., Patterson, V., LaCasce, A. S., Bello, C. M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Dacarbazine Hodgkin's lymphoma Immunotherapy Lymphoma Monoclonal antibodies Radiation Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue	S2
container_start_page
container_title	Hematological oncology
container_volume	39
creator	Abramson, J. S. Bengston, E. M. Redd, R. Barnes, J. A. Takvorian, T. Sokol, L. Lansigan, F. Armand, P. Shah, B. Jacobsen, E. Martignetti, R. Turba, E. Metzler, S. R. Patterson, V. LaCasce, A. S. Bello, C. M.
description
doi_str_mv	10.1002/hon.110_2880
format	Article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2541698762</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2541698762</sourcerecordid><originalsourceid>FETCH-LOGICAL-c652-766d8ee9b637b1aa2bb689ad9c19a988c829af4a933863b116576df54588260c3</originalsourceid><addsrcrecordid>eNo1kcFO3DAQhi1UJLbAjQcYqVcCtrNx7KM38W4skniVONDtJUqyWRXUbpYEDr31EfoSfTGeBCPgNBrNN_NL8yF0QfAVwZhe_xz2V4TgmnKOj9CMYCE8gpn4gmaYhtzD1Kcn6Os0PWDsZpjP0P9M2qpQUKiySm0Jy8JkIGGdyFKB1mALLVMwS1gUKrfVd53JBdyq2FidwzqtSpCxQ7JN5HqZxxDLSBYL-UPnCu60TUxloZCxllabHByUm_zl779Fld5sINWZtiqG0sqVgiiVZakjl5eYeHXj2HSTrROTyTN0vGt-Tf35Rz1FdqlslHipWb0teB0LqBcytuV9L1rmhy1pGtq2jItmKzoiGsF5x6lodvNG-D5nfksIC0K23QXzgHPKcOefom_vZw_j8PjcT0_1w_A87l1iTYM5YYKHjDrq8p3qxmGaxn5XH8b73834p3avf_NQOw_1pwf_FSSrbuE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2541698762</pqid></control><display><type>article</type><title>MATURE RESULTS FROM A PHASE II TRIAL OF BRENTUXIMAB VEDOTIN PLUS ADRIAMYCIN AND DACARBAZINE WITHOUT RADIATION IN NON‐BULKY LIMITED STAGE CLASSICAL HODGKIN LYMPHOMA</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Abramson, J. S. ; Bengston, E. M. ; Redd, R. ; Barnes, J. A. ; Takvorian, T. ; Sokol, L. ; Lansigan, F. ; Armand, P. ; Shah, B. ; Jacobsen, E. ; Martignetti, R. ; Turba, E. ; Metzler, S. R. ; Patterson, V. ; LaCasce, A. S. ; Bello, C. M.</creator><creatorcontrib>Abramson, J. S. ; Bengston, E. M. ; Redd, R. ; Barnes, J. A. ; Takvorian, T. ; Sokol, L. ; Lansigan, F. ; Armand, P. ; Shah, B. ; Jacobsen, E. ; Martignetti, R. ; Turba, E. ; Metzler, S. R. ; Patterson, V. ; LaCasce, A. S. ; Bello, C. M.</creatorcontrib><identifier>ISSN: 0278-0232</identifier><identifier>EISSN: 1099-1069</identifier><identifier>DOI: 10.1002/hon.110_2880</identifier><language>eng</language><publisher>Chichester: Wiley Subscription Services, Inc</publisher><subject>Dacarbazine ; Hodgkin's lymphoma ; Immunotherapy ; Lymphoma ; Monoclonal antibodies ; Radiation ; Targeted cancer therapy</subject><ispartof>Hematological oncology, 2021-06, Vol.39 (S2)</ispartof><rights>2021 John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Abramson, J. S.</creatorcontrib><creatorcontrib>Bengston, E. M.</creatorcontrib><creatorcontrib>Redd, R.</creatorcontrib><creatorcontrib>Barnes, J. A.</creatorcontrib><creatorcontrib>Takvorian, T.</creatorcontrib><creatorcontrib>Sokol, L.</creatorcontrib><creatorcontrib>Lansigan, F.</creatorcontrib><creatorcontrib>Armand, P.</creatorcontrib><creatorcontrib>Shah, B.</creatorcontrib><creatorcontrib>Jacobsen, E.</creatorcontrib><creatorcontrib>Martignetti, R.</creatorcontrib><creatorcontrib>Turba, E.</creatorcontrib><creatorcontrib>Metzler, S. R.</creatorcontrib><creatorcontrib>Patterson, V.</creatorcontrib><creatorcontrib>LaCasce, A. S.</creatorcontrib><creatorcontrib>Bello, C. M.</creatorcontrib><title>MATURE RESULTS FROM A PHASE II TRIAL OF BRENTUXIMAB VEDOTIN PLUS ADRIAMYCIN AND DACARBAZINE WITHOUT RADIATION IN NON‐BULKY LIMITED STAGE CLASSICAL HODGKIN LYMPHOMA</title><title>Hematological oncology</title><subject>Dacarbazine</subject><subject>Hodgkin's lymphoma</subject><subject>Immunotherapy</subject><subject>Lymphoma</subject><subject>Monoclonal antibodies</subject><subject>Radiation</subject><subject>Targeted cancer therapy</subject><issn>0278-0232</issn><issn>1099-1069</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNo1kcFO3DAQhi1UJLbAjQcYqVcCtrNx7KM38W4skniVONDtJUqyWRXUbpYEDr31EfoSfTGeBCPgNBrNN_NL8yF0QfAVwZhe_xz2V4TgmnKOj9CMYCE8gpn4gmaYhtzD1Kcn6Os0PWDsZpjP0P9M2qpQUKiySm0Jy8JkIGGdyFKB1mALLVMwS1gUKrfVd53JBdyq2FidwzqtSpCxQ7JN5HqZxxDLSBYL-UPnCu60TUxloZCxllabHByUm_zl779Fld5sINWZtiqG0sqVgiiVZakjl5eYeHXj2HSTrROTyTN0vGt-Tf35Rz1FdqlslHipWb0teB0LqBcytuV9L1rmhy1pGtq2jItmKzoiGsF5x6lodvNG-D5nfksIC0K23QXzgHPKcOefom_vZw_j8PjcT0_1w_A87l1iTYM5YYKHjDrq8p3qxmGaxn5XH8b73834p3avf_NQOw_1pwf_FSSrbuE</recordid><startdate>202106</startdate><enddate>202106</enddate><creator>Abramson, J. S.</creator><creator>Bengston, E. M.</creator><creator>Redd, R.</creator><creator>Barnes, J. A.</creator><creator>Takvorian, T.</creator><creator>Sokol, L.</creator><creator>Lansigan, F.</creator><creator>Armand, P.</creator><creator>Shah, B.</creator><creator>Jacobsen, E.</creator><creator>Martignetti, R.</creator><creator>Turba, E.</creator><creator>Metzler, S. R.</creator><creator>Patterson, V.</creator><creator>LaCasce, A. S.</creator><creator>Bello, C. M.</creator><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7QP</scope><scope>7T7</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>202106</creationdate><title>MATURE RESULTS FROM A PHASE II TRIAL OF BRENTUXIMAB VEDOTIN PLUS ADRIAMYCIN AND DACARBAZINE WITHOUT RADIATION IN NON‐BULKY LIMITED STAGE CLASSICAL HODGKIN LYMPHOMA</title><author>Abramson, J. S. ; Bengston, E. M. ; Redd, R. ; Barnes, J. A. ; Takvorian, T. ; Sokol, L. ; Lansigan, F. ; Armand, P. ; Shah, B. ; Jacobsen, E. ; Martignetti, R. ; Turba, E. ; Metzler, S. R. ; Patterson, V. ; LaCasce, A. S. ; Bello, C. M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c652-766d8ee9b637b1aa2bb689ad9c19a988c829af4a933863b116576df54588260c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Dacarbazine</topic><topic>Hodgkin's lymphoma</topic><topic>Immunotherapy</topic><topic>Lymphoma</topic><topic>Monoclonal antibodies</topic><topic>Radiation</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abramson, J. S.</creatorcontrib><creatorcontrib>Bengston, E. M.</creatorcontrib><creatorcontrib>Redd, R.</creatorcontrib><creatorcontrib>Barnes, J. A.</creatorcontrib><creatorcontrib>Takvorian, T.</creatorcontrib><creatorcontrib>Sokol, L.</creatorcontrib><creatorcontrib>Lansigan, F.</creatorcontrib><creatorcontrib>Armand, P.</creatorcontrib><creatorcontrib>Shah, B.</creatorcontrib><creatorcontrib>Jacobsen, E.</creatorcontrib><creatorcontrib>Martignetti, R.</creatorcontrib><creatorcontrib>Turba, E.</creatorcontrib><creatorcontrib>Metzler, S. R.</creatorcontrib><creatorcontrib>Patterson, V.</creatorcontrib><creatorcontrib>LaCasce, A. S.</creatorcontrib><creatorcontrib>Bello, C. M.</creatorcontrib><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Hematological oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abramson, J. S.</au><au>Bengston, E. M.</au><au>Redd, R.</au><au>Barnes, J. A.</au><au>Takvorian, T.</au><au>Sokol, L.</au><au>Lansigan, F.</au><au>Armand, P.</au><au>Shah, B.</au><au>Jacobsen, E.</au><au>Martignetti, R.</au><au>Turba, E.</au><au>Metzler, S. R.</au><au>Patterson, V.</au><au>LaCasce, A. S.</au><au>Bello, C. M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MATURE RESULTS FROM A PHASE II TRIAL OF BRENTUXIMAB VEDOTIN PLUS ADRIAMYCIN AND DACARBAZINE WITHOUT RADIATION IN NON‐BULKY LIMITED STAGE CLASSICAL HODGKIN LYMPHOMA</atitle><jtitle>Hematological oncology</jtitle><date>2021-06</date><risdate>2021</risdate><volume>39</volume><issue>S2</issue><issn>0278-0232</issn><eissn>1099-1069</eissn><cop>Chichester</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1002/hon.110_2880</doi></addata></record>
fulltext	fulltext
identifier	ISSN: 0278-0232
ispartof	Hematological oncology, 2021-06, Vol.39 (S2)
issn	0278-0232 1099-1069
language	eng
recordid	cdi_proquest_journals_2541698762
source	Wiley Online Library Journals Frontfile Complete
subjects	Dacarbazine Hodgkin's lymphoma Immunotherapy Lymphoma Monoclonal antibodies Radiation Targeted cancer therapy
title	MATURE RESULTS FROM A PHASE II TRIAL OF BRENTUXIMAB VEDOTIN PLUS ADRIAMYCIN AND DACARBAZINE WITHOUT RADIATION IN NON‐BULKY LIMITED STAGE CLASSICAL HODGKIN LYMPHOMA
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T22%3A38%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MATURE%20RESULTS%20FROM%20A%20PHASE%20II%20TRIAL%20OF%20BRENTUXIMAB%20VEDOTIN%20PLUS%20ADRIAMYCIN%20AND%20DACARBAZINE%20WITHOUT%20RADIATION%20IN%20NON%E2%80%90BULKY%20LIMITED%20STAGE%20CLASSICAL%20HODGKIN%20LYMPHOMA&rft.jtitle=Hematological%20oncology&rft.au=Abramson,%20J.%20S.&rft.date=2021-06&rft.volume=39&rft.issue=S2&rft.issn=0278-0232&rft.eissn=1099-1069&rft_id=info:doi/10.1002/hon.110_2880&rft_dat=%3Cproquest_cross%3E2541698762%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2541698762&rft_id=info:pmid/&rfr_iscdi=true